Multiple myeloma is characterized by frequent chromosomal alterations. Deletion of chr 13, especially band 13q14, is commonly observed in early stages of MM, suggesting the presence of tumor suppressor genes within this region. Here, we functionally validate the role of the microRNAs-15a/16-1 cluster, centered at the deleted region, as TSGs and delineate their downstream target genes in MM. Using 
Introduction
Multiple myeloma (MM) is a mature B cell neoplasm characterized by clonal proliferation of plasma cells in bone marrow (BM), which is typically preceded from Monoclonal Gammopathy of Undetermined Significance (MGUS). MM is characterized by multiple chromosomal aberrations 1, 2 seen in more than 50% of patients at diagnosis. The most common one is deletion of 13q14 3 . Interestingly, this region overlaps with a minimal common region (MCR) deletion identified in chronic lymphocytic leukemia (CLL) and in other lymphoid malignancies 2, [4] [5] [6] [7] . Using highresolution analysis of array comparative genomic hybridization (aCGH), we and others 4, 8 have identified a 10 MB MCR that is consistently deleted at 13q14, its presence correlating with high risk of recurrent patients. Being lost at the initial stages of the disease as well as in MGUS, this region, suspected to harbor tumor suppressor genes (TSGs), was associated with the downregulation of several resident genes including miR-15a and -16.
MicroRNAs are small regulatory RNAs that regulate gene expression by inducing translational inhibition and degradation of their target mRNAs 9, 10 . They regulate various biological processes by posttranslational regulation about 30% of all genes 11 .
When studied in CLL [12] [13] [14] [15] , miR-15a/16-1 cluster is believed to be one of the deleted TSGs residing at the 13q14 MCR. Over-expression of miR-16 in a megakaryocytic leukemia cell line caused induction of apoptosis and downregulation of BCL2 15, 16 . In MM, endogenous low levels of miR-15a/16-1 have been correlated with high risk staging, and in an overexpressing system using gain-of-function (GOF) approaches they were shown to induce growth arrest 17, 18 . Nonetheless, being lost in CLL, MM and other hematological malignancies, their functional role has not been studied using loss-of-function (LOF) approaches in any of the lymphoid malignancies as it has been in prostate cancer, in which 13q14 deletion is found at progression 19 . Moreover, a systematic, unbiased approach to determine their direct and secondary targets has not been undertaken and only few very selective targets have been studied. We describe the generation of an in vivo system for the long term, stable knockdown of miR-15a/16-1 in MM cells to recapitulate the conditions seen in 13q14 deleted MM 9, 19 . Using this system, we show that inhibition of miR-15a/16-1 promotes proliferation, as well as pro-angiogenic and invasive properties of MM cells, by directly up-regulation of numerous oncogenes and altering multiple signaling pathways. This pleiotropic effect in gene expression is cell type specific and mediated via binding not only to conserve sites in the 3'-UTR but also through binding to sites located within the coding region. Thus, we have generated a valuable preclinical system to investigate the functional role of miR-15a/16-1 in disease pathogenesis and their potential use as therapeutic targets in MM.
Materials and Methods
Cells and stable cell line production. CD138+ and CD138-BM mononuclear cells were prepared using CD138 microbeads (Milteny Biotech) 22 . Approval for these studies was obtained from DFCI Institutional Review Board. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki 22 . MM cell lines were collected from different sources
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. The GFP-sponge16 or GFP-sponge CXCR4 DNA fragment was removed from the previously described vector 9 using
BamH1 and ApaI sites and cloned into lentiviral pHAGE-CMV/UBC-GFP vector.
Cells were infected using lentiviral particles and sorted by using the GFP marker as previously described 4, 24, 25 . The pRS-miR-15a/16-1 and control vectors were kind gifts from Dr. George A. Calin 15, 16 .
Gene expression profiling (GEP), aCGH and miRNA analyis. GEP and aCGH data for MM primary tumors were previously described 4 . RNA from MMS1 and RPMI cells expressing control sponge or sponge16 were hybridized on an Affymetrix 
Quantitative reverse transcription polymerase chain reaction (q-RT-PCR).
cDNA was made using SuperScript cDNA synthesis kit (Invitrogen) and q-RT-PCR reactions using SYBR master mix (Fermentas) with designated primers relative to β -Actin expression (SI table 4 ) by Mastercycler thermocycler (Eppendorf) in triplicates.
For primary MM samples, reactions were performed using the miScript kit (Qiagen) with a miR-16-specific primer relative to snoRNA (Promega) expression.
Northern blots (NB), immunoblots (IB) and in situ hybridization (ISH) analysis.
NB, IB and ISH were performed as previously described 9, 24, 25, 32 . Antibodies from Cell Signaling included: 
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For personal use only. on April 30, 2017. by guest www.bloodjournal.org From miRNA reporter assays. cDNA fragments of target genes were amplified using the designated primers (SI Table 4 ) to generate 250-600bp fragments, cloned to the downstream of the stop codon of the Rluc reporter using XhoI/ApaI sites.
Mutagenesis of the miR-16 reporter plasmids were carried out with a QuikChange Lightning Muti Site-Directed Mutagenesis Kit (Stratagene) using designed oligonucleotides (SI Table 4 ). All plasmids were verified by sequencing. Luciferase reporters for miR-16 target genes were assayed and normalized relative to the control reporter and PGL luciferase measurements 9 . Experiments were done in triplicate and repeated three times. deletion were transduced and sorted for GFP expression. In MM cell lines as well as in 293T cells, the sp16 long term cultured cells were able to suppress the levels of miR-16 by ~50%, as evaluated by NB (Fig. 1A) as well as their repressive activity, by functional luciferase reporter assays (Fig. 1B) . The amount of supression was reproduced in several MM cell lines tested (SI Fig. 1A ). As controls, miR-16 was Fig. 1B) . In SI- Fig 1C and D, we documented that the suppression is specific for both miR-15a and miR-16, not occuring with a miRNA from a different seed family, such as miR-20. In addition, as expected, this activity had also an inhibitory effect on miR-15b, a superfamily member (SI Fig. 1D ).
Xenograft murine model, histology and immunohistochemistry (IHC
miR-15a/16-1 inhibition enhances proliferation of MM cells in vitro. To determine the functional role of miR-15a/16, MMS1 cells were transduced using the above described lentiviral system. Sp16 cells showed a significant increase in growth rates (1.5-2 fold) compared with controls, as measured by cell counting (Fig. 1C) , viability assay (Fig. 1D) or [H] 3 thymidine uptake (Fig. 1E) . We also compared the spCX The growth increase observed in sp16 cells was associated with a significant increase in S and G2/M phases in MMS1 and other cell lines (SI Fig. 1G ). In accord with previous studies, we observed that miR-16 target genes including BCL2 15 , Cyclin D1 6 and CDC25a 33 are upregulated in sp16 cells (SI Fig. 1H ). For personal use only. on April 30, 2017. by guest www.bloodjournal.org From identified the top 100 genes that were differentially upregulated in sp16 cells as compared to spCX cells ( Fig. 2A, left) . Using functional annotation groups by the DAVID online tool 28, 29 , highly significant GO clustering of genes related to growth and cell cycle was observed among upregulated genes (SI Table 1 and Fig. 2A , right).
GEP analysis in miR-
Applying the Pictar and Targetscan analyses, 16% of the top 100 genes were predicted to be direct targets of the miR-16 family (whereas a random list predicted by the same analysis 7%, p=0.02). Furthermore, when testing for a possible 7-bp seed binding of miR-16 to the full-length mRNA of those genes using the RNAhybrid module 30 , we found that 59% of genes were predicted targets of miR-16, some at multiple sites (SI Table 2 ). Using a less stringent cutoff with a logFC of more than 0.2 in both cell lines for top up-regulated genes, we identified multiple pathways involved in tumor growth, oncogenesis, invasiveness and progression. The pathway that was most prominently affected is the MAPK signaling pathway (SI Table 3 ); however, several other genes that synergize with this pathway, such as PI3K pathway, VEGF related genes, FGFR1, and PKC were also affected, in addition to TP53 via the MDM4 oncogene. Apart from these signaling pathways, other genes and pathways involved in tumor progression including Jag1, JUN, NEDD9, Snai2, and VEGFa were also significantly up-regulated. Intriguingly, β-globin and δ-globin were among the most up-regulated genes. 3B ). However, some of these proteins were differentially expressed in 293T sp16 cells, suggesting that the effect of miRNA downregulation is cell type-specific. In addition, and as expected if the changes in gene expression were specific to the levels of miR-15a/16, most of these proteins were down-regulated in the over-expressing cell lines (SI Fig. 3C ).
Since these results have implicated the miR-15a/16-1 cluster in the regulation of several genes involved in tumor progression, invasiveness, and angiogenesis, we further validated these findings functionally by measuring VEGF secretion in MMS1 cells. Secretion of VEGF was enhanced under inhibition of miR-15a/16-1 and reduced in the overexpressing control cells (Fig. 2D) . We also tested the invasive capacity of the cells in matrigel, and found that sp16 cells show a three-fold increase in invasiveness (Fig. 2E ). In addition, because the growth of MM cells is enhanced by the BM microenvironment 22 we confirmed that, although attenuated, the proliferative advantage of the sp16 cells is maintained even in the presence of BM stromal cells (Fig. 2F) . To further show the functional relevance of these up-regulated pathways, cells were incubated in the presence of LY249002, a pan-PI3K inhibitor, or enzastaurin, a pan-PKC inhibitor (Fig. 2G) . Both agents exerted a low, albeit significant, inhibitory effect in the sp16 cells as compared with their controls, consistent with their partial addiction to these pathways. In contrast, sp16 cells were not more sensitive, but were in fact more resistant, to the conventional MM therapies of adriamycin and melphalan (SI Figs. 4A and B). Another common treatment used in MM is the proteasome inhibitor bortezomib, which showed a significant inhibitory activity on the sp16 cells as compared with their spCX controls (SI Fig. 4C ).
Overall, these results implicate miR-15a/16-1 in the regulation of multiple pathways and genes, contributing to their pleiotropic oncogenic properties. Our LOF system allowed the functional examination of specific drugs for the treatment of malignancies with defined loss of tumor-suppressor miR-15a/16.
miR-15a/16-1 directly target genes both in the 3' UTR and in the coding region.
The above results prompted us to investigate whether miR-15a/16-1 affected putative target genes in a direct manner. Since FGFR1 was predicted to have a conserved miR-
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O N A P R I L 2 6 , 2 0 1 1 16 binding site in its 3'-UTR (Fig. 3A) , we cloned this DNA fragment into the Rluciferase vector, and probed its expression in 293T cells (Fig. 3B) . The relative luciferase expression was higher in sp16 cells as compared with their controls, and lower in pRS16 cells as compared with their controls, implying that FGFR1 is a direct target of miR-16. Since many more genes, including PI3Kα, PI3KC2A and MDM4, were predicted direct targets of miR-16 by its binding within the coding region of the mRNA (Fig. 3A) , we cloned one putative binding sites for PI3Kα, one for PI3KC2A, and one for MDM4 into the R-luciferase vector, and show that the level of luciferase activity was also directly affected by miR-15a/16-1 levels (Fig. 3B) . The specificity of miRNAs interaction was further corroborated by using reporter vectors containing mutated predicted binding sites, which showed no reporter activity in miR-16 knockdown as well as overexpression cells once mutated (Fig. 3B ). Taken together, our results support pleiotropic effects of miR-16 by its binding to multiple genes at 3'-UTR regions, as well as within coding regions.
miR-15a/16-1 inhibition decreased survival in a xenograft mouse model of MM.
To investigate the impact on survival in vivo, sp16 or spCX cells were injected into sub-lethally irradiated mice. Transplanted animals were evaluated over time and survival was plotted for Kaplan-Meier analysis. All animals developed hind limb paralysis or died from day 25 to day 104. The median survival for mice injected with sp16 or spCX cells was 31 days versus 80 days, respectively (p<0.0001) (Fig. 4A) .
Interestingly, sp16 cells not only grew more rapidly, but also spread to more anatomical sites, evidenced by frequent intraparenchymal GFP-positive nodules ( (Fig. 5B) . We also examined the samples, in accord to our findings of VEGF upregulation, for blood vessels formation, and found that albeit no change in numbers, the 13q14 deleted samples evidently had more prominent and larger blood vessels (Fig. 5C ). We next used our previously published GEP data on MM patient samples for which we have aCGH data 4 to compare gene expression levels of the target genes 
Discussion
The miR-15a/16-1 cluster is believed to be a TSG residing at the 13q14 MCR 4, 8, 19 .
In CLL, these two miRNAs were shown to have reduced levels in more than 50% of patients, and to correlate with a distinct signature tied to prognosis. At the functional level, it has been documented that over-expression of miR-16 causes induction of apoptosis and growth arrest 15, 16, 18 . In prostate cancer, they were lost along cancer progression and their downregulation caused cellular overgrowth The observation that this susceptibility was relatively mild supports the view that many pathways are being up-regulated in parallel and that addiction for each pathway is only partial. Our LOF system could be utilized to screen for better inhibitors and drug combinations to treat tumors with defined miR-15a/16-1 loss. Additionally, the The finding of numerous genes regulated by miR-15a/16-1 is not surprising. Previous studies found a few genes affected including BCL2 15, 16 , Wnt3a 19 and AKT 18 . We identified 16% of the up-regulated genes by GEP to be predicted as direct targets by Pictar and Targetscan, which have conserved binding sites in the 3'-UTR of the mRNA. This number is consistent with previously published GEP studies done with miRNAs treated cells 16 . We also used the RNA hybrid module 28, 29 , which examines miR-16 pairing to the entire mRNA sequence, and found that many more of the top up-regulated genes have putative miR-16 binding site(s). We validated this finding by Thus, we showed that many different genes are being affected and this regulation is mediated through the miR-16 specific binding to both the 3'-UTR and/or coding regions. This finding, rarely reported for miRNA direct targeting [48] [49] [50] , supports the notion that each miRNA has many more targets than are assessed by these bioinformatics algorithms 51 . We also found that the sponge had an inhibitory effect on miR-15b, another superfamily member. As in many biological systems, there is a Since there is a tremendous heterogeneity within myeloma, it is difficult to compare these reports. Moreover, when we looked at the expression of miR-15a/16-1 target genes in clinically annotated MM primary samples, no significant statistical differences in the expression of miR-15a/16-1 target genes was observed between MM primary samples with or without 13q14 deletion. These results may be due to the 
R E T R A C T E D

